These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 14567637)

  • 41. Polymorphism in nimodipine raw materials: development and validation of a quantitative method through differential scanning calorimetry.
    Riekes MK; Pereira RN; Rauber GS; Cuffini SL; de Campos CE; Silva MA; Stulzer HK
    J Pharm Biomed Anal; 2012 Nov; 70():188-93. PubMed ID: 22795312
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s).
    Green SA; Rathz DA; Schuster AJ; Liggett SB
    Eur J Pharmacol; 2001 Jun; 421(3):141-7. PubMed ID: 11516429
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects.
    Guhan AR; Cooper S; Oborne J; Lewis S; Bennett J; Tattersfield AE
    Thorax; 2000 Aug; 55(8):650-6. PubMed ID: 10899240
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Determination of salmeterol in metered-dose and dry-powder inhalers by reversed-phase high performance liquid chromatography.
    Nayak VG; Belapure SG; Gaitonde CD; Sule AA
    J Pharm Biomed Anal; 1996 Feb; 14(4):511-3. PubMed ID: 8729651
    [No Abstract]   [Full Text] [Related]  

  • 45. Comparative physicochemical characterization of phospholipids complex of puerarin formulated by conventional and supercritical methods.
    Li Y; Yang DJ; Chen SL; Chen SB; Chan AS
    Pharm Res; 2008 Mar; 25(3):563-77. PubMed ID: 17828444
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stability and aerodynamic behaviour of glucocorticoid particles prepared by a supercritical fluids process.
    Velaga SP; Bergh S; Carlfors J
    Eur J Pharm Sci; 2004 Mar; 21(4):501-9. PubMed ID: 14998581
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Crystallization of D-mannitol in binary mixtures with NaCl: phase diagram and polymorphism.
    Telang C; Suryanarayanan R; Yu L
    Pharm Res; 2003 Dec; 20(12):1939-45. PubMed ID: 14725357
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The characterization and comparison of spray-dried mannitol samples.
    Hulse WL; Forbes RT; Bonner MC; Getrost M
    Drug Dev Ind Pharm; 2009 Jun; 35(6):712-8. PubMed ID: 19514986
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Salmeterol xinafoate in children on high dose inhaled steroids.
    Russell G; Williams DA; Weller P; Price JF
    Ann Allergy Asthma Immunol; 1995 Nov; 75(5):423-8. PubMed ID: 7583864
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of salmeterol xinafoate in the treatment of COPD.
    Mahler DA; Donohue JF; Barbee RA; Goldman MD; Gross NJ; Wisniewski ME; Yancey SW; Zakes BA; Rickard KA; Anderson WH
    Chest; 1999 Apr; 115(4):957-65. PubMed ID: 10208192
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization and Thermodynamic Relationship of Three Polymorphs of a Xanthine Oxidase Inhibitor, Febuxostat.
    Patel J; Jagia M; Bansal AK; Patel S
    J Pharm Sci; 2015 Nov; 104(11):3722-3730. PubMed ID: 26178598
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Crystallization of pure anhydrous polymorphs of carbamazepine by solution enhanced dispersion with supercritical fluids (SEDS).
    Edwards AD; Shekunov BY; Kordikowski A; Forbes RT; York P
    J Pharm Sci; 2001 Aug; 90(8):1115-24. PubMed ID: 11536216
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Determination of salmeterol in rat and dog plasma by high-performance liquid chromatography with fluorescence detection.
    Colthup PV; Young GC; Felgate CC
    J Pharm Sci; 1993 Mar; 82(3):323-5. PubMed ID: 8095543
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma.
    Korosec M; Novak RD; Myers E; Skowronski M; McFadden ER
    Am J Med; 1999 Sep; 107(3):209-13. PubMed ID: 10492312
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects.
    Bennett JA; Tattersfield AE
    Thorax; 1997 May; 52(5):458-64. PubMed ID: 9176539
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel flow through diffusion cell for assessing drug transport across the buccal mucosa in vitro.
    Lestari ML; Nicolazzo JA; Finnin BC
    J Pharm Sci; 2009 Dec; 98(12):4577-88. PubMed ID: 19408309
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Surface energy changes and their relationship with the dispersibility of salmeterol xinafoate powders for inhalation after storage at high RH.
    Das S; Larson I; Young P; Stewart P
    Eur J Pharm Sci; 2009 Nov; 38(4):347-54. PubMed ID: 19732829
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quantitative determination of two polymorphic forms of imatinib mesylate in a drug substance and tablet formulation by X-ray powder diffraction, differential scanning calorimetry and attenuated total reflectance Fourier transform infrared spectroscopy.
    Bellur Atici E; Karlığa B
    J Pharm Biomed Anal; 2015 Oct; 114():330-40. PubMed ID: 26099262
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical pharmacokinetics of salmeterol.
    Cazzola M; Testi R; Matera MG
    Clin Pharmacokinet; 2002; 41(1):19-30. PubMed ID: 11825095
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Study of retinoic acid polymorphism.
    Caviglioli G; Pani M; Gatti P; Parodi B; Cafaggi S; Bignardi G
    J Pharm Sci; 2006 Oct; 95(10):2207-21. PubMed ID: 16883553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.